14.47 0.00 (0.00%)
After hours: 4:58PM EDT
|Bid||12.00 x 800|
|Ask||30.13 x 1200|
|Day's Range||14.18 - 14.96|
|52 Week Range||8.88 - 23.55|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.50|
Replimune Group Inc. (REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that a trial in progress (TiP) poster will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL from May 31 to June 4, 2019. The poster will describe the design and current status of the Company’s ongoing Phase 1/2 clinical trial in approximately 150 patients of RP1 alone and in combination with nivolumab anti-PD1 therapy in four solid tumor types, and will be made available on the Company’s website at the time of presentation.
Small-cap biotech Replimune's lead asset RP1, a genetically modified herpes virus that serves to boost the virus' ability to kill tumor cells, is likely to be successful, Driscoll said in the Wednesday initiation note.
WOBURN, Mass., April 01, 2019 -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform,.
RP1: Completed Single Agent Enrollment in Part 1 Portion of Phase 1/2 Clinical Trial in the UK;Part 1 Enrollment Opened for Combination with Nivolumab in Patients with Solid.
WOBURN, Mass., Feb. 07, 2019 -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform, today.
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...
“Replimune had a very productive 2018 with our successful initial public offering in July providing us with the funds to continue to advance our new generation of potentially best in class oncolytic immuno-gene therapies into and through clinical trials,” said Robert Coffin, Ph.D., co-founder, President and CEO of Replimune.
WOBURN, Mass., Dec. 20, 2018 -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform, today.
The elite funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don’t follow. Because of their pay structures, they have strong incentive to do the research necessary […]
WOBURN, Mass., Dec. 05, 2018 -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform, today.
Investment company Bain Capital Life Sciences Investors, LLC buys Replimune Group Inc during the 3-months ended 2018-09-30, according to the most recent filings of the investment company, Bain Capital ...
U.S. Clinical Sites for Phase 1/2 Trial of RP1 in Patients with Solid Tumors on Track to Initiate by End of Year Additional Product Candidates RP2 and RP3 Continue to Advance.
Biotech Replimune Group, Inc. (NASDAQ: REPL ), which conducts research and cancer treatment studies using oncolytic viruses, picked up a sell-side bull Tuesday. The Analyst BMO Capital Markets analyst ...